You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Aberration-correcting Topologically Optimized Metasurface (ATOM)
SBC: PHYSICAL SCIENCES INC. Topic: HR001119S003524Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...
STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency -
A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation
SBC: REBISCAN, Inc. Topic: NProject Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
A novel device for cervical insufficiency in pregnant women
SBC: Cx Therapeutics, Inc Topic: NICHDAbstract In normal pregnancy, the cervix remains closed until term and then dilates under the influence of uterine contractions. In cases of cervical insufficiency (CI), the cervix dilates in the second trimester in the absence of uterine contractions, which leads to a preterm birth. Infants born prematurely are at risk of lifelong morbidities including chronic lung disease, feeding difficulties, ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Chemically controlling chromatin to treat Friedriech's Ataxia
SBC: Epigenos Bioscience, Inc. Topic: NCATSWe recently developed a technology that combines catalytically inactive dCas9 with bifunctional chemicals that link endogenous host cellular machinery to specific genes targeted with dCas9. We have demonstrated this technology can significantly increase gene expression at multiple endogenous mammalian genes in a chemically dependent manner. Here we propose to apply this technology to the mono-alle ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Continuum Actuated Redundant Tendon Robots
SBC: OPTERUS RESEARCH AND DEVELOPMENT, INC Topic: HR001119S003523Opterus Research and Development, Inc. (Opterus) and Colorado State University (CSU) have combined the best features of high strain composites (HSC), continuum robots, and tendon actuated robots to develop a new concept called Continuum Actuated Redundant Tendon (CART) Robot to enable self-reconfigurable modular robots that can perform various tasks (e.g., walking, crawling, wheeling, and grasping ...
STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency -
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion
SBC: Bedrock Therapeutics, Inc. Topic: NHLBIAdeno-associated virus (AAV) vectors have been successfully applied in clinical trials in patients with hemophilia. Two AAV based gene therapy drugs have been recently approved by the FDA. Luxturna has been valued at $850,000 for a one-time treatment for a rare form of blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. Gene therapy with AAV vectors has shown a potentially huge market ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Developing novel technologies to monitor nociception and opioid administration during surgery and general anesthesia in order to minimize post-operative opioid requirements
SBC: PASCALL Systems, Incorporated Topic: NIDAPROJECT SUMMARY In light of the opioid crises, minimizing postoperative pain and postoperative opioid requirements to reduce chronic opioid dependency among surgical patients have become major concerns for surgeons and anesthesiologists. Effective intraoperative nociception control can mitigate these concerns. Unfortunately, existing nociceptive monitoring tools use indicators that are inherently ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis
SBC: Arrevus, Inc. Topic: NIAIDPROJECT SUMMARYSepsis is a life-threatening syndrome that involves a systemic inflammatory response that is initiated by an infection. There are an estimated 1.5 million of cases annually in the US with 250,000 resulting in death. The number of cases and associated deaths is expected to increase given the rising at-risk population of elderly individuals and the compounding challenge of antibiotic ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of a tool to examine proteomic pathways in the AD brain
SBC: ProteoWise Inc. Topic: NIAAbstract For the extent of our careers as Alzheimer’s researchers, we have struggled with the limitations imposed by the standard techniques for protein analysis. Western blot, the go-to protein technology of the bench researcher, is no match for the complex brain protein distortions of AD. To remedy this debility, we devised a technology that we are making available to all researchers through t ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Development of EFTX-001 to target KRAS mutations in cancer
SBC: ENFUEGO THERAPEUTICS, INC. Topic: 102Research Summary: The KRAS proto-oncogene is one of the most critical genes in cancer, yet it has also proven to be among the most elusive. Nearly all (98%) of KRAS missense mutations occur in codons 12 or 13, which leads to constitutive KRAS activation and promotion of numerous cancer hallmarks. Although kinase inhibitors have revolutionized treatment of some subsets of cancers driven by other mo ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health